UK-based drugmaker Shire Pharmaceuticals has been boosted this week by the regulatory approval in Sweden of its kidney disease drug Fosrenol. This breakthrough should now pave the way for wider EU approval in the second half of 2004. With the upcoming patent expiry of Adderall putting future revenue at risk, Fosrenol has become a particularly significant drug for the future prospects of Shire.
Long-term studies have shown biomarkers to be effective in predicting those with mild cognitive impairment that will go on to develop Alzheimer's disease. Such a test could help companies developing new therapies for delaying or preventing the onset of Alzheimer's, and, by identifying the need for treatment early, could improve both drug uptake and treatment success rates.
The positive results of a second Phase III trial have added to the anticipation for Dymista, Meda's nasal steroid/antihistamine combination for allergic rhinitis. In line for first-to-market status, the combination will be a welcome addition to current treatment options.
Edit my basket
© Datamonitor 2012. All rights reserved
Terms & Conditions